» Articles » PMID: 35178454

Understanding the Critical Role of Glycolysis-Related LncRNAs in Lung Adenocarcinoma Based on Three Molecular Subtypes

Overview
Journal Biomed Res Int
Publisher Wiley
Date 2022 Feb 18
PMID 35178454
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Glycolysis is closely associated with tumor progression, but the roles of lncRNAs in glycolysis have not been comprehensively investigated in lung adenocarcinoma (LUAD). This study is aimed at studying the possible mechanisms of glycolysis-related lncRNAs in tumor development and providing a guidance for targeted therapy.

Methods: Unsupervised consensus clustering was used to identify molecular subtypes. Gene enrichment analysis was applied to screen important pathways involved in tumor progression. A series of immune analysis was performed to assess immune infiltration. Critical transcription factors (TFs) interacting with lncRNAs were selected by Pearson correlation analysis. A first-order partial correlation analysis was implemented to identify critical lncRNAs with prognostic significance.

Results: Three molecular subtypes (C1, C2, and C3) were identified with distinct overall survival. Three subtypes showed differential immune infiltration, and C3 subtype was the optimal for immunotherapy treatment. Ten lncRNA-TF pairs among four glycolysis-related lncRNAs (FTX, LINC00472, PSMA3-AS1, and SNHG14) and six TFs (FOXP1, SP1, MYC, FOXM1, HIF1A, and FOS) were involved in tumor progression. We identified four critical glycolysis-related lncRNAs significantly associated with prognosis.

Conclusions: This study identified three molecular subtypes that could guide personalized therapy. The four-lncRNA prognostic model can serve as an indicator for predicting prognosis or early screening of lung adenocarcinoma patients. The current results improve the understanding of the relation between lncRNAs and glycolysis.

Citing Articles

LINC00908 attenuates LUAD tumorigenesis through DEAD-box helicase 54.

Zhao J, Yang X, Gong W, Zhang L, Li C, Han X Am J Cancer Res. 2024; 14(5):2371-2389.

PMID: 38859824 PMC: 11162691. DOI: 10.62347/HXZM6394.


Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine.

Bajinka O, Ouedraogo S, Golubnitschaja O, Li N, Zhan X EPMA J. 2024; 15(2):289-319.

PMID: 38841622 PMC: 11147999. DOI: 10.1007/s13167-024-00357-5.


Retracted: Understanding the Critical Role of Glycolysis-Related lncRNAs in Lung Adenocarcinoma Based on Three Molecular Subtypes.

International B Biomed Res Int. 2024; 2024:9891572.

PMID: 38550168 PMC: 10977192. DOI: 10.1155/2024/9891572.


Interaction and Collaboration of SP1, HIF-1, and MYC in Regulating the Expression of Cancer-Related Genes to Further Enhance Anticancer Drug Development.

Kimura K, Jackson T, Huang R Curr Issues Mol Biol. 2023; 45(11):9262-9283.

PMID: 37998757 PMC: 10670631. DOI: 10.3390/cimb45110580.

References
1.
Byun J, Schwartz A, Lusk C, Wenzlaff A, de Andrade M, Mandal D . Genome-wide association study of familial lung cancer. Carcinogenesis. 2018; 39(9):1135-1140. PMC: 6148967. DOI: 10.1093/carcin/bgy080. View

2.
Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

3.
Xu N, Jia D, Chen W, Wang H, Liu F, Ge H . FoxM1 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor metastasis. PLoS One. 2013; 8(3):e59412. PMC: 3607616. DOI: 10.1371/journal.pone.0059412. View

4.
Wang L, Cao L, Wen C, Li J, Yu G, Liu C . LncRNA LINC00857 regulates lung adenocarcinoma progression, apoptosis and glycolysis by targeting miR-1179/SPAG5 axis. Hum Cell. 2019; 33(1):195-204. DOI: 10.1007/s13577-019-00296-8. View

5.
Curtin N . DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer. 2012; 12(12):801-17. DOI: 10.1038/nrc3399. View